NPY2R and metastatic malignant neoplasm in the lymph nodes: Notably, the odds ratio was significantly higher in patients with no lymph node metastasis (n = 100) in whom the NPY2R promoter was methylated versus unmethylated (odds ratio, 2.492; 95% CI, 1.190–5.215; P = 0.015) (Table 3).